Purpose: CD81 is a prognostic biomarker for high-grade bladder cancer (BC). In this study, we aimed to determine the functional mechanisms underlying the role of CD81 in BC progression.
INTRODUCTION
Bladder cancer (BC) is the second most common cancer of the three major urological cancers (i.e., prostate, bladder, and kidney cancer), with a worldwide incidence of 541,000 in 2015, which led to 188,000 deaths [1] . Non-muscle invasive BC (NMIBC) comprises 70% of pTa, 20% of pT1, and 10% of carcinoma in situ [2, 3] , while 30% to 80% of NMIBC patients experience recurrence and 3% to 45% of NMIBC patients undergo progression to muscle invasive BC (MIBC) within five years [4, 5] . The recurrence of NMIBC and progression to MIBC have a significant impact on patient quality of life as well as survival, thus the identification of a prognostic biomarker is an important issue. Our previous study found that CD81 was one such biomarker for high grade BC [6] , and we demonstrated that an inverse correlation between membranous CD81 expression and adverse pathological characteristics existed and had prognostic value in BC.
CD81, a member of the tetraspanin family, is a cell surface protein expressed in most tissues and tumor cells [7] . It plays an important role in cell organization, protein trafficking, cellular fusion, and cell-cell interactions, and is associated with cell signaling molecules such as protein kinase C, extracellular signal-regulated kinase (ERK), mitogen-activated protein kinase (MAPK), Ras, and Rac [8] . CD81 is also involved in B and T cell activation in the immune system and affects tumor growth and metastasis through the regulation of T regulatory cell function [9] [10] [11] [12] . In several cancers such as breast and lung cancer, hepatocellular carcinoma, and melanoma, CD81 expression was reported to be associated with cancer progression [13] [14] [15] [16] [17] . However, in other cancers (e.g., stomach cancer and multiple myeloma), CD81 expression was found to inhibit tumor progression [18, 19] . As such, the role of CD81 in cancer progression may be cancer type-dependent. In any case, the CD81 mechanism of action in different cancers remains unclear.
Although CD81 has been identified as a biomarker of BC in a limited number of studies [6, 20] , no study to date has evaluated a functional mechanism for CD81 in BC. In this study, we sought to investigate the functional mechanism of CD81 in BC progression through in vitro modulation of CD81 expression in BC cells.
MATERIALS AND METHODS

Ethics statement
The study protocol was approved by the Institutional Review Board of the Eulji University Hospital (approval number: 2018-07-010).
Cell culture
BC cell lines (T24, J82) were obtained from the Korean Cell Line Bank. T24 and J82 cells were cultured in Dulbecco's Modified Eagle's medium (DMEM; Corning Life Science, Corning, NY, USA) and RPMI 1640 medium (Lonza, Allendale, NJ, USA) supplemented with 10% fetal bovine serum (FBS; Hyclone, Logan, UT, USA), respectively. The cells were maintained in a humidified atmosphere of 5% CO 2 at 37 o C.
Lentivirus infections
Plasmids containing shRNA for human CD81 (TRCN-0000382433 and TRCN0000300293; Sigma, St. Louis, MO, USA), scramble plasmid for shRNA (#1864; Addgene, Cambridge, MA, USA), and CD81 overexpression vector (pCDH; SBI, Palo Alto, CA, USA) were co-transfected with pPACKF1 packaging plasmid mix (SBI) into Lenti-X 293T cells (Takara, Otsu, Japan) using X-tremeGENE HP DNA transfection reagent (Sigma) according to the manufacturer's protocol. BC cells were infected with viral supernatants from 293T cells along with polybrene (5 μg/ mL) for 24 hours. After 10 days of selection with puromycin (0.5 μg/mL), an efficiency of CD81 knockdown was evaluated by flow cytometry and western blotting.
Flow cytometry for CD81
BC cells were resuspended in 1% of FBS/phosphatebuffered saline (PBS) (v/v) and stained with anti-CD81 antibody (Santa Cruz Biotechnology, Dallas, TX, USA) at 4 o C for 30 minutes. For labeling, allophycocyanin-conjugated anti-mouse IgG (R&D systems, Minneapolis, MN, USA) was used as a secondary antibody. After washing with PBS, the cells were analyzed with a Guava easyCyte Flow Cytometer (Merck Millipore, Bedf ord, MA, USA) and InCyte 3.1 software (Merck Millipore).
Western blot
BC cell proteins were isolated using a 1X sodium dodecyl sulfate (SDS) buffer containing 62.5 mM Tris-HCL at pH 6.8, 2% (w/v) SDS, 10% glycerol, 50 mM dithiothreitol, and 0.01% (w/v) bromophenol blue. The cell suspension was boiled for 10 minutes and centrifuged at 13,000×g for 10 minutes. The proteins were resolved by electrophoresis in a 10% SDS polyacrylamide gel and transferred to a nitrocellulose blotting membrane (GE Healthcare, Little Chalfont, UK). The membrane was blocked with 5% skim milk. Mouse polyclonal anti-CD81 antibody (Santa Cruz Biotechnology), rabbit anti-Akt antibody (Bioss Antibodies Inc., Woburn, MA, USA), rabbit anti-phospho-Akt antibody (Cell Signaling Technology, Beverly, CA, USA), mouse anti-ERK antibody (Bioss Antibodies Inc.), anti-phospho-ERK (Bioss Antibodies Inc.), rabbit anti-p38 antibody (Bioss Antibodies Inc.), rabbit anti-c-Jun N-terminal kinases (JNK) antibody (Bioss Antibodies Inc.), anti-phospho-JNK (Santa Cruz Biotechnology), rabbit anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Cusabio, Houston, TX, USA), rabbit anti-MMP2 antibody (Bioss Antibodies Inc.), rabbit anti-MMP9 antibody (Bioss Antibodies Inc.) were used as primary antibodies. Horseradish peroxidase-conjugated anti-rabbit or anti-mouse antibodies (Bethyl Laboratories Inc., Montgomery, TX, USA) were used as secondary antibodies. The results were visualized with enhanced chemiluminescence detection reagent (Bio-Rad, Hercules, CA, USA) and a ChemiDoc Touch Imaging System (Bio-Rad).
Invasion assay
The membrane within the insert (BD Biosciences, San Jose, CA, USA) was coated with matrigel. BC cells, at 4×10 4 cells/well, were introduced into the cell culture insert and incubated at 37 o C for 18 hours. After incubation, the membrane was stained with crystal violet.
MTT assay
Cell proliferation was measured by MTT assay. About 1×10 4 cells/well were seeded into 96-well plates and incubated for 1 hour or 72 hours, the cells were incubated with 0.5 mg/mL of thiazolyl blue tetrazolium bromide (MTT) solution at 37 o C for 4 hours. The solution was replaced with dimethylsulfoxide (DMSO), and the optical densities were determined at 540 nm and 630 nm using a microplate reader (Molecular Devices, San Jose, CA, USA). The data are representative of three independent experiments performed in triplicate.
Zymography
For the zymographic assay, cells were cultured in DMEM without FBS for 48 hours. Conditioned media (CM) was collected and centrifuged at 2,000×g for 10 minutes. CM was concentrated with an Amicon Ultra-2 Centrifugal Filter Unit (Merck Millipore) and the concentrated CM was normalized for cell number. Proteins in the normalized CM were then separated by electrophoresis in a 10% polyacrylamide gel impregnated with 2 mg/mL gelatin (Sigma). After electrophoresis, the gels were washed in 2.5% Triton X-100 for 30 minutes and then incubated in zymogram development solution buffer (50 mm Tris-HCl, 5 mM CaCl 2 dissolved in distilled water) for 24 hours at 37 o C. This buffer was changed every 4 hours, and stained with 0.2% Coomassie Blue.
Statistical analysis
All data were obtained from at least three independent experiments and were analyzed by two-tailed unpaired Student's t-tests. All continuous variables are shown as mean±standard deviation. A p-value <0.05 was considered Functional mechanisms of CD81 in bladder cancer statistically significant.
RESULTS
Knockdown of CD81 in BC cells
Given that decreased CD81 expression was associated with BC invasion in our prior study [6] , we tried to suppress the expression of CD81 in two invasive BC cell lines (T24, J82) using CD81-specific shRNAs. Empty vector was used as a control and two shRNAs against a different region of CD81 was applied to each cell line. After 10 days of culture of the shRNA-transfected cells with selective antibiotics, the expression of CD81 was analyzed (Fig. 1A) . Following flow cytometry, an obvious suppression of CD81 expression was observed in both cell lines with shRNAs as compared to the control (Fig. 1A) . Western blot analyses were consistent with these results (Fig. 1B) .
Migration and invasive activity of CD81-suppressed BC cells
To assess the effect of CD81 knockdown on the migration and invasion of BC cells, transwell migration and invasion assays were performed. Migration increased slightly in CD81-knockdown cells as compared to control cells, but the difference was not significant (Fig. 2A) . However, the invasive activity of CD81-knockdown cells was significantly (Fig. 2B) , indicating that CD81 was associated with the invasive activity of BC cells. To analyze the correlation between cell proliferation and invasive activity, proliferation of CD81-knockdown cells was analyzed by MTT assay after 72 hours of culture (Fig. 2C, D) . While proliferation of T24 cells was decreased by CD81 knockdown, CD81-knockdown J82 cells showed slightly increased proliferation rate. These findings indicated that CD81 knockdown did not have consistent effects on BC cell proliferation and there was no correlation between cell proliferation and invasive activity.
Enzymatic activity and expression of MMPs in CD81-suppressed BC cells
To elucidate the relevant cause of the increased invasive activity of CD81-knockdown BC cells, the enzymatic activity and expression of MMPs was analyzed by zymography and western blotting. Obvious bands of MMPs were observed in our zymogram (Fig. 3A) with supernatants from CD81-knockdown cells, whereas only faint bands were observed with empty vector-transfected cells. Specifically, the CD81-knockdown T24 cells had a higher expression of MMP2 than control cells, while CD81-knockdown J82 cells showed a higher expression of MMP9 than control cells (Fig. 3A) . We confirmed the increased expression of MMP2 and 9 in the CM from CD81-knockdown T24 and J82 cells, respectively, by western blotting (Fig. 3B). 
Screening for signaling pathways in CD81-knockdown BC cells
To identify signaling proteins involved in increased MMP expression in CD81-knockdown BC cells, the expression of various proteins in MMP2/9-associated signaling pathways was analyzed by western blot. Among the examined proteins, only phosphorylated ERK (p-ERK) was increased in both CD81-knockdown T24 (Fig. 4A ) and J82 cells (Fig. 4B) , compared with control, indicating that increased p-ERK in the MAPK pathway may lead to increased expression of MMP2/9.
In order to examine the effect of inhibition of ERK phosphorylation on the invasive activity of CD81-knockdown BC cells, T24 and J82 cells were treated with U0126 (ERK 
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inhibitor) or DMSO (control). ERK phosphorylation and the invasive activity of BC cells were analyzed by western blot and invasion assay, respectively. ERK phosphorylation was successfully inhibited by a non-toxic level of U0126 (10 μM) in both T24 and J82 cells (Fig. 5A ). While invasive activity was increased in CD81-knockdown cells, treatment with U0126 suppressed the invasion of CD81-knockdown cells to a level similar to those of control cells (Fig. 5B) . These findings suggest that the invasive activity of CD81-knockdown BC cells is mediated by ERK phosphorylation.
Overexpression of CD81 in BC cells
To assess the ef fect of CD81 overexpression on the invasive property of BC cells, we overexpressed CD81 using a lentivirus system. BC cells were infected with lentivirus containing control vectors or CD81 overexpression vectors, and then CD81 expression was analyzed by western blot (Fig. 6) . While both T24 and J82 cells showed overexpression of CD81 by lentivirus infection, the expression of p-ERK was unaffected. These results suggest that a basal level of CD81 in BC cells might be sufficient to suppress the phosphorylation of ERK.
DISCUSSION
Previous studies have shown conflicting results regarding the function of CD81 in cancer progression [16] [17] [18] [19] , and the functional mechanism of CD81 in BC has not been investigated. Our study was the first to identify the functional mechanism of CD81 in BC progression.
We found that the suppression of CD81 in BC cells pro- moted BC cell invasion, but did not significantly affect cell migration. As alluded to above, previous studies in several cancers have reported conflicting results with regard to the effect of CD81 expression on cancer cell migration and invasion. For instance, in a study of multiple myeloma, overexpression of CD81/82 resulted in decreased cell migration and invasion potential [18] . In contrast, a study of melanoma showed that CD81 overexpression resulted in increased cell migration and invasion [16] . Similar to melanoma, overexpression of CD81 in breast cancer increased cell migration [17] . Given these previous studies in conjunction with our current study, it is apparent that the effect of CD81 on cancer cell migration and invasion is dependent upon the cancer type. Our data also show that the suppression of CD81 promotes the expression of MMPs, specifically MMP2 and MMP9. MMPs are zinc-containing endopeptidases expressed in connective tissue and inflammatory cells, which are regulated by hormones, growth factors and cytokines. MMPs play an important role in tissue remodeling in a variety of physiological or pathological processes (e.g., bone morphogenesis, the menstrual cycle, development, arthritis, atherosclerosis, and cancer invasion) [21, 22] . Upregulation of MMPs has been identified to promote cancer progression by promoting cancer cell growth, migration, invasion, and metastasis in almost every type of human cancer [23] . In particular, upregulation of MMP2 and MMP9 in BC is known to be associated with cancer progression and poor survival, which is consistent with our findings [24] [25] [26] . Of note, though MMPs promote the progression of most cancers, differences exist in the association between CD81 expression and MMPs depending on the cancer type. In line with our BC results, CD81/82 overexpression in multiple myeloma reduced MMP9 secretion, and attenuated cell adherence, motility, and invasive potential [18] . However, in a study of breast cancer, knocking down two or three of the tetraspanin proteins (CD9, CD81, TSPAN2) reduced cancer cell invasion and growth by decreasing the function of membrane type 1(MT1)-MMP [15] . Moreover, a melanoma study has also shown that CD81 induces MT1-MMP expression, leading to the migration, invasion, and metastasis of cancer cells [16] .
The conflicting results on the role of CD81 in cancer progression [15] [16] [17] [18] indicate that its mechanism of action is mediated by MMP through other factors that are downstream of CD81. As a potential downstream mediator of CD81, we found that p-ERK in the MAPK pathway is involved in BC tumor invasion. Specifically, increased p-ERK following CD81 suppression, induced the increased expression of MMP2/9, and consequently resulted in increased BC cell invasion.
ERK is a signaling substance that plays an important role in cell proliferation, survival, migration, differentiation, and apoptosis via a related pathway (e.g., the MAPK pathway) in various cancers [27] . Prior studies have sug gested possible mediators of CD81 signaling in several cancers. In liver tumor cells, CD81 leads to cell proliferation and activation of ERK/MAPK, which is involved in Shc [14] . A study of melanoma showed that CD81 induces MT1-MMP expression through Akt-dependent Sp1 activation [16] . Moreover, in gastric cancer, the suppression of CD81 may provide benefits to tumor cell growth and survival through p38 phosphorylation [19] . While these other studies have suggested other mediators of CD81 such as Shc, Aktdependent Sp1 and p38, we found that ERK phosphorylation plays a role in BC progression through increased MMP expression af ter CD81 suppression. Our f inding that treatment with the ERK phosphorylation inhibitor, U0126, suppressed the invasion of CD81-knockdown cells ( 
CONCLUSIONS
We demonstrated that CD81 suppression promotes the invasion of BC cells by increased MMP expression via ERK phosphorylation. Further studies are needed to elucidate the signaling mediators between membranous CD81 and p-ERK expression. Our results suggest that there may be some therapeutic benefit in regulating CD81 by modulating ERK phosphorylation in BC.
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